OpenAI's AI model solved the so-called unit distance problem. The problem was posed by the mathematician Paul Erdลs around 80 years ago and had remained unsolved ever since. Several prominent mathematicians confirm that the solution is on par with work produced by humans.
Researchers at MIT have developed mini livers that can be injected into the body and take over functions from a failing liver. The technology could help patients who are currently not healthy enough for a transplant.
A year ago, Warp News reported on AlphaEvolve, an AI system from Google DeepMind that finds new algorithms in mathematics and computer science. Now Google has reported what the system has accomplished over the past year, in everything from genomics to power grids and data processing.
Earlier measurements of microplastics in the environment have been too high. The cause is residue from common lab gloves that was counted as plastic. Now researchers have developed a way to separate glove residue from actual microplastics.
The researchers found no statistical link between more AI text and more factual errors online. Fears that writing styles, source links, and meaningful content would deteriorate were not confirmed in the measurements either.
Median wealth rose by nearly 400 percent between 1999 and 2020. The richest 10 percent reduced their share of total wealth from 67 to 57 percent. The share of adults with no net wealth fell from 21 to 16 percent.
A single dose of the gene therapy VERVE-102, given as an infusion, lowered harmful cholesterol as much as today's medications do with repeated treatment. At the highest dose, harmful cholesterol fell by an average of 62 percent.
The immune system can now be used to treat several types of cancer, and more than 2,500 immunotherapies are in development. Cancer vaccines have also started to show results in clinical trials, against melanoma, pancreatic cancer, and brain tumors, among others.
Among women with breast cancer, more than 95 percent of GLP-1 users were alive after five years, compared to 89.5 percent of non-users. Women who had taken a GLP-1 drug had about 25 percent lower risk of receiving a breast cancer diagnosis.